Imagine living with HIV for over a decade and facing the daily challenges of frailty as you age. This is the reality for many older adults, who often find that their physical strength and ability to perform everyday tasks diminish over time. A new clinical trial is exploring whether a combination of two drugs, dasatinib and quercetin, can help improve physical function for these individuals. In this study, 80 participants aged 50 and older will receive either the drug combination or a placebo over 12 weeks. The goal is to see if this treatment can enhance their ability to walk and carry out daily activities. If successful, this could mean a significant improvement in quality of life for older adults with HIV, allowing them to regain some of the physical abilities they may have lost. However, it’s important to remember that this is still a trial, and results will take time to analyze. The hope is that these findings could lead to new treatments that help older adults with HIV live healthier, more active lives.
Can a New Drug Combination Help Older Adults with HIV Regain Strength?
Plain Language Summary
What this means for you:
A new drug combo could help older adults with HIV regain strength and improve their quality of life. What this means for you:
A new drug combo could help older adults with HIV regain strength and improve their quality of life. View Original Abstract ↓
Status: ACTIVE_NOT_RECRUITING | Phase: PHASE2
Condition(s): HIV, Frailty, Prefrail, Aging Problems
Intervention(s): Dasatinib (DRUG), Quercetin (DRUG), Placebo - Dasatinib (OTHER), Placebo - Quercetin (OTHER)
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression.
Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects.
The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Primary Outcome(s): Occurrence of Grade 2 or higher adverse events (AEs) after initiation of study treatment.; Occurrence of premature treatment discontinuations.; Absolute change in gait speed on 4-meter walk.
Enrollment: 82 (ACTUAL)
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Start: 2025-12-04 | Primary Completion: 2026-11-29